Mapping of the p53 and mdm-2 interaction domains.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Molecular and Cellular Biology

• Publication date

  1993-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/MCB.13.7.4107PMID 7686617PMCID PMC359960
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The p53-mdm-2 autoregulatory feedback loop.

  1993cited by this paper
• MDM2 gene amplification in metastatic osteosarcoma.

  1993cited by this paper
• Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

  1992cited by this paper
• Wild-type p53 activates transcription in vitro

  1992cited by this paper
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

  1992cited by this paper
• Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein

  1992cited by this paper
• Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

  1992cited by this paper
• p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.

  1992cited by this paper
• Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.

  1992cited by this paper
• A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization.

  1992cited by this paper
• Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element.

  1992cited by this paper
• Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.

  1992cited by this paper
• The transcriptional transactivation function of wild‐type p53 is inhibited by SV40 large T‐antigen and by HPV‐16 E6 oncoprotein.

  1992cited by this paper
• Oncogenic forms of p53 inhibit p53-regulated gene expression.

  1992cited by this paper
• Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.

  1992cited by this paper
• Amplification of a gene encoding a p53-associated protein in human sarcomas

  1992cited by this paper
• THE P53 TUMOR SUPPRESSOR GENE

  1991cited by this paper
• A structural taxonomy of DNA-binding domains

  1991cited by this paper
• Mutant p53 proteins bind DNA abnormally in vitro.

  1991cited by this paper
• Participation of p53 protein in the cellular response to DNA damage.

  1991cited by this paper
• Identification of p53 as a sequence-specific DNA-binding protein

  1991cited by this paper
• Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.

  1991cited by this paper
• The p53 tumour suppressor gene

  1991cited by this paper
• Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

  1991cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.

  1991cited by this paper
• Association of human papillomavirus types 16 and 18 E6 proteins with p53.

  1990cited by this paper
• Structural aspects of the p53 protein in relation to gene evolution.

  1990cited by this paper
• Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.

  1990cited by this paper
• The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

  1990cited by this paper
• Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins.

  1990cited by this paper
• Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome

  1990cited by this paper
• Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis

  1990cited by this paper
• Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

  1990cited by this paper
• The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses.

  1990cited by this paper
• Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins.

  1989cited by this paper
• Mutations in the p53 gene occur in diverse human tumour types

  1989cited by this paper
• The p53 proto-oncogene can act as a suppressor of transformation.

  1989cited by this paper
• Wild-type p53 can inhibit oncogene-mediated focus formation.

  1989cited by this paper
• Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life

  1988cited by this paper
• Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

  1988cited by this paper
• Two distinct regions of the murine p53 primary amino acid sequence are implicated in stable complex formation with simian virus 40 T antigen

  1988cited by this paper
• Meth A fibrosarcoma cells express two transforming mutant p53 species.

  1988cited by this paper
• Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line

  1987cited by this paper
• ‘Zinc fingers’: a novel protein motif for nucleic acid recognition

  1987cited by this paper
• Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex

  1986cited by this paper
• Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells.

  1982cited by this paper
• Monoclonal antibodies specific for simian virus 40 tumor antigens

  1981cited by this paper
• Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.

  1979cited by this paper
• T antigen is bound to a host protein in SY40-transformed cells

  1979cited by this paper
• DNA sequencing with chain-terminating inhibitors.

  1977cited by this paper

• Ribosome biogenesis rate, a parameter of sensitivity to chemotherapeutic drugs inhibiting rRNA synthesis

  2026cites this paper
• The Structure, Pathogenesis, and Inhibition of the p53-MDM2 Pathway.

  2026cites this paper
• A cancer persistent DNA repair circuit driven by MDM2, MDM4 (MDMX), and mutant p53 for recruitment of MDC1 and 53BP1 on chromatin

  2025cites this paper
• Δ133p53α and Δ160p53α isoforms of the tumor suppressor protein p53 exert dominant-negative effect primarily by co-aggregation

  2025cites this paper
• Research Progress on PCR (Plant Cadmium Resistance) Genes in Plants

  2025cites this paper
• Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia

  2025cites this paper
• Advances in polycythemia vera treatment with targeted therapies and clinical trials

  2025cites this paper
• Development of MDM2‐Targeting PROTAC for Advancing Bone Regeneration

  2025cites this paper
• Citrullination at the N‐terminal region of MDM2 by the PADI4 enzyme

  2025influential citation
• A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT.

  2025cites this paper
• Ubiquitin E3 Ligases and p53 in Doxorubicin-Induced Cardiotoxicity

  2025cites this paper
• NFAT activation by FKBP52 promotes cancer cell proliferation by suppressing p53

  2024cites this paper
• MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

  2024cites this paper
• An update patent review of MDM2–p53 interaction inhibitors (2019–2023)

  2024cites this paper
• Deciphering the Multi-state Conformational Equilibrium of HDM2 in the Regulation of p53 Binding: Perspectives from Molecular Dynamics Simulation and NMR Analysis.

  2024cites this paper
• Activation of p53 signaling and regression of breast and prostate carcinoma cells by spirooxindole-benzimidazole small molecules

  2024cites this paper
• A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN

  2024cites this paper
• Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance

  2024cites this paper
• Azurin-Based Peptide p28 Arrests the p53-HDM2 Interactions: A Novel Anti-Cancer Pathway

  2024cites this paper
• Structural adaptation of secondary p53 binding sites on MDM2 and MDMX.

  2024cites this paper
• Rational design of small-sized peptidomimetic inhibitors disrupting protein-protein interaction.

  2024cites this paper
• Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens

  2023cites this paper
• The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer

  2023cites this paper
• New insights into cancer: MDM2 binds to the citrullinating enzyme PADI4

  2023cites this paper
• Potential Benefits of Dietary Plant Compounds on Normal and Tumor Brain Cells in Humans: In Silico and In Vitro Approaches

  2023cites this paper
• Roles of NOLC1 in cancers and viral infection

  2023cites this paper
• Murine herpesvirus-68-related growth factors treatment correlates with decrease of p53 and HIF-1α protein levels

  2023cites this paper
• Conformational Stability of the N-Terminal Region of MDM2

  2023cites this paper
• The Development of p53-Targeted Therapies for Human Cancers

  2023cites this paper
• TRIB3 promotes pulmonary fibrosis through inhibiting SLUG degradation by physically interacting with MDM2

  2023cites this paper
• MDM2 binds and ubiquitinates PARP1 to enhance DNA replication fork progression.

  2022influential citation
• Small-molecule MDM2 inhibitors in clinical trials for cancer therapy.

  2022cites this paper
• Electronic Polarization at the Interface between the p53 Transactivation Domain and Two Binding Partners.

  2022cites this paper
• Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups

  2022cites this paper
• The correlation between MDM2 SNP309 T > G polymorphism and hepatocellular carcinoma risk – A meta-analysis

  2022cites this paper
• Time‐series transcriptomics and proteomics reveal alternative modes to decode p53 oscillations

  2022cites this paper
• Functional Antibody Delivery: Advances in Cellular Manipulation.

  2022cites this paper
• The role of miRNAs in MDMX‐p53 interplay

  2021cites this paper
• Small molecules targeting misfolded mutants of p53 as a rescue strategy to improve glioblastoma chemotherapy

  2021cites this paper
• High Glucose Treatment Limits Drosha Protein Expression and Alters AngiomiR Maturation in Microvascular Primary Endothelial Cells via an Mdm2-dependent Mechanism

  2021cites this paper
• Development and structural characterisation of human scFv targeting MDM2 spliced variant MDM215kDa.

  2021cites this paper
• Cancer-Associated Mutations Perturb the Disordered Ensemble and Interactions of the Intrinsically Disordered p53 Transactivation Domain.

  2021cites this paper
• Regulation of p53 by E3s

  2021cites this paper
• The ion channel TRPM7 regulates zinc-depletion-induced MDMX degradation

  2021cites this paper
• Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma

  2020cites this paper
• Cancer-Associated Mutations Perturb the Structure and Interactions of the Intrinsically Disordered p53 Transactivation Domain

  2020influential citation
• Expression of the long noncoding RNA DINO in HPV positive cervical cancer cells reactivates the dormant TP53 tumor suppressor through ATM/CHK2 signaling

  2020cites this paper
• DoMY-Seq: A yeast two-hybrid–based technique for precision mapping of protein–protein interaction motifs

  2020cites this paper
• Establishment and characterisation of testicular cancer patient-derived xenograft models for preclinical evaluation of novel therapeutic strategies

  2020cites this paper
• Multiple biochemical properties of the p53 molecule contribute to activation of polymerase iota-dependent DNA damage tolerance

  2020cites this paper
• CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells

  2020cites this paper
• Towards reconstructing the dipteran demise of an ancient essential gene: E3 ubiquitin ligase Murine double minute

  2020cites this paper
• Photoinduced synthesis and antitumor activity of a phakellistatin 18 analog with an isoindolinone fragment

  2020cites this paper
• Host cell p53 associates with the feline calicivirus major viral capsid protein VP1, the protease-polymerase NS6/7, and the double-stranded RNA playing a role in virus replication

  2020cites this paper
• The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276

  2020cites this paper
• Structural basis for DNA damage-induced phosphoregulation of MDM2 RING domain

  2020cites this paper
• Expression of the Long Noncoding RNA DINO in Human Papillomavirus-Positive Cervical Cancer Cells Reactivates the Dormant TP53 Tumor Suppressor through ATM/CHK2 Signaling

  2020cites this paper
• UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination

  2020cites this paper
• Policing Cancer: Vitamin D Arrests the Cell Cycle

  2020cites this paper
• UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination

  2020cites this paper
• PPIs as therapeutic targets for anticancer drug discovery: the case study of MDM2 and BET bromodomain inhibitors

  2020cites this paper
• Mass Spectrometry-Based Protein Footprinting for Higher-Order Structure Analysis: Fundamentals and Applications.

  2020cites this paper
• p53: An Attractive Therapeutic Target for Cancer.

  2020cites this paper
• Crosstalk Between Vitamin D and p53 Signaling in Cancer: An Update.

  2020cites this paper
• A Single Conserved Amino Acid Residue as a Critical Context-Specific Determinant of the Differential Ability of Mdm2 and MdmX RING Domains to Dimerize

  2019cites this paper
• Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway

  2019cites this paper
• Do Mutations Turn p53 into an Oncogene?

  2019cites this paper
• HOPS/TMUB1 retains p53 in the cytoplasm and sustains p53‐dependent mitochondrial apoptosis

  2019influential citation
• Improving cancer therapy with new p53-activating agents

  2019cites this paper
• p53 Protein: Master Regulator of Apoptosis and its Application in Cancer Therapy

  2019cites this paper
• MiR-135b-5p promotes viability, proliferation, migration and invasion of gastric cancer cells by targeting Krüppel-like factor 4 (KLF4)

  2019cites this paper
• Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.

  2019cites this paper
• CD4+-Zelldepletion durch MDM2-Deletion vermindert bei Mäusen die Nierenschädigung in der akuten und in der späten Phase der nephrotoxischen Serum-Nephritis

  2019cites this paper
• The C-terminal SAM domain of p73 binds to the N terminus of MDM2.

  2019cites this paper
• Solution structure of MUL1-RING domain and its interaction with p53 transactivation domain.

  2019cites this paper
• The multiple mechanisms that regulate p53 activity and cell fate

  2019cites this paper
• A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)

  2019influential citation
• Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis

  2018cites this paper
• Retinoic acid–induced survival effects in SH‐SY5Y neuroblastoma cells

  2018cites this paper
• Mathematical Modeling Identification of Active Sites Interaction of Protein Molecules

  2018cites this paper
• Distinct control of PERIOD2 degradation and circadian rhythms by the oncoprotein MDM2

  2018influential citation
• Generation of reporter cell lines by genome editing to probe p53 activity

  2018cites this paper
• Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding.

  2018cites this paper
• p53 and metabolism: from mechanism to therapeutics

  2018cites this paper
• Novel metabolic regulations exerted by LKB1 signaling in polarized cells : impact on tissue ontogeny

  2018cites this paper
• Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity

  2018cites this paper
• Distinct control of PERIOD2 degradation and circadian rhythms by the oncoprotein and ubiquitin ligase MDM2

  2018cites this paper
• Sensitive and simultaneous surface plasmon resonance detection of free and p53-bound MDM2 proteins from human sarcomas.

  2018cites this paper
• Hyperglycaemia correlates with skeletal muscle capillary regression and is associated with alterations in the murine double minute-2/forkhead box O1/thrombospondin-1 pathway in type 1 diabetic BioBreeding rats

  2018cites this paper
• Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers

  2018cites this paper
• Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner.

  2017cites this paper
• Title In vitro selection of mutant HDM 2 resistant to nutlininhibition

  2017cites this paper
• Podozyten-spezifischer Murine Double Minute (MDM) 2 Knockout führt zu fokal segmentaler Glomerulosklerose

  2017cites this paper
• Stabilization of HIF-1α and HIF-2α, up-regulation of MYCC and accumulation of stabilized p53 constitute hallmarks of CNS-PNET animal model

  2017cites this paper
• Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells

  2017cites this paper
• Long Non-Coding RNA MEG3 Downregulation Triggers Human Pulmonary Artery Smooth Muscle Cell Proliferation and Migration via the p53 Signaling Pathway

  2017cites this paper
• Artificial Macrocycles as Potent p53–MDM2 Inhibitors

  2017cites this paper
• C-terminal region of human p53 attenuates buffalo p53 N-terminal-specific transactivation of p21 promoter by modulating tetramerization of the protein

  2017cites this paper
• Co-operative intra-protein structural response due to protein–protein complexation revealed through thermodynamic quantification: study of MDM2-p53 binding

  2017cites this paper
• The Transactivation Domains of the p53 Protein.

  2017cites this paper